776 Spam-Free Article(s) Found
Sort:
Date
Filter:
All
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Wednesday’s Close
BMY Bristol-Myers Squibb Company $61.3 $100.03B Uptrend
Article Searches
Pharma Stock Roundup: AZN Inks Cancer Deal, ABBV, NVS & Others Get Drug Approvals http://www.zacks.com/stock/news/367176/pharma-stock-roundup-azn-inks-cancer-deal-abbv-nvs-others-get-drug-approvals?cid=CS-ZC-FT-367176 Mar 29, 2019 - AstraZeneca announces a $6.9 billion cancer deal with Daiichi Sankyo. AbbVie (ABBV), Novartis (NVS) & AstraZeneca's (AZN) drugs get regulatory approvals.
J&J Files sBLA for Darzalex in Expanded Myeloma Patient Group http://www.zacks.com/stock/news/365606/jj-files-sbla-for-darzalex-in-expanded-myeloma-patient-group?cid=CS-ZC-FT-365606 Mar 27, 2019 - J&J (JNJ) submits sBLA seeking approval for Darzalex combination regimen in newly-diagnosed, transplant eligible multiple myeloma patient population
Celgene (CELG) Submits NDA for MS Drug to FDA for Review http://www.zacks.com/stock/news/365034/celgene-celg-submits-nda-for-ms-drug-to-fda-for-review?cid=CS-ZC-FT-365034 Mar 26, 2019 - Celgene (CELG) progresses with the development of its MS candidate, as it submits an application for the same to the FDA.
J&J Files Application for Darzalex Label Expansion in Europe http://www.zacks.com/stock/news/364217/jj-files-application-for-darzalex-label-expansion-in-europe?cid=CS-ZC-FT-364217 Mar 25, 2019 - J&J (JNJ) seeks an approval for Darzalex combo pertaining to the newly diagnosed, transplant-ineligible multiple myeloma patient population in the EU.
Why Bristol-Myers Squibb (BMY) is a Great Dividend Stock Right Now http://www.zacks.com/stock/news/363083/why-bristol-myers-squibb-bmy-is-a-great-dividend-stock-right-now?cid=CS-ZC-FT-363083 Mar 22, 2019 - Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Bristol-Myers Squibb (BMY) have what it takes? Let's find out.
Bristol-Myers' Celgene Buyout Still Uncertain Amid Opposition http://www.zacks.com/stock/news/362782/bristol-myers-celgene-buyout-still-uncertain-amid-opposition?cid=CS-ZC-FT-362782 Mar 21, 2019 - The acquisition deal between Bristol-Myers and Celgene faces opposition from stakeholders of Bristol-Myers. The future of the deal depends on the outcome of the Special Meeting in April.
Starboard vs. Bristol-Myers Squibb: Who'll Win This Brewing Battle? https://www.fool.com/investing/2019/03/19/starboard-vs-bristol-myers-squibb-and-celgene-whol.aspx?source=iedfolrf0000001 Mar 19, 2019 - An activist investor made a strong argument for walking away from Celgene, but will investors listen?
Roche's Tecentriq Gets FDA Approval for Difficult Lung Cancer http://www.zacks.com/stock/news/361461/roches-tecentriq-gets-fda-approval-for-difficult-lung-cancer?cid=CS-ZC-FT-361461 Mar 19, 2019 - Roche (RHHBY) gets an FDA approval of sBLA for Tecentriq in combination with chemotherapy for the first-line treatment of extensive-stage small cell lung cancer (ES-SCLC).
Bristol-Myers & Pfizer Release Phase IV Data on Eliquis http://www.zacks.com/stock/news/360914/bristol-myers-pfizer-release-phase-iv-data-on-eliquis?cid=CS-ZC-FT-360914 Mar 18, 2019 - Bristol-Myers (BMY) and partner Pfizer ) announce results from the phase IV - AUGUSTUS study evaluating Eliquis (apixaban) versus vitamin K antagonists (VKAs).
Novartis' (NVS) Alcon Acquired PowerVision for $285 Million http://www.zacks.com/stock/news/360866/novartis-nvs-alcon-acquired-powervision-for-%24285-million?cid=CS-ZC-FT-360866 Mar 18, 2019 - Novartis' (NVS) eye-care unit, Alcon acquires PowerVision to drive growth in advanced technology intraocular lenses (AT-IOLS) for cataract surgery patients.

Pages: 12345678910...78

<<<Page 5>